Wanbury Ltd Q2 FY26 – When Metformin Meets Masala Finance: The Pharma Comeback Nobody Saw Coming
1. At a Glance
Ladies and gentlemen, please welcome Wanbury Ltd, the pharma phoenix that refuses to die. Once dismissed as just another small API player, this ₹908 crore mid-cap has pulled off a recovery that’s as dramatic as a Bollywood climax. The stock closed at ₹260 (28 Nov 2025), not exactly a multibagger move this quarter—but enough to make long-term holders whisper, “Chalo, ab toh kuch ban raha hai.”
In the latest Q2 FY26 results (September 2025), Wanbury clocked Revenue of ₹160 crore, EBITDA of ₹26 crore, and a PAT of ₹15.2 crore, registering a jaw-dropping 89% YoY profit growth. For a company that once lived in the shadow of its debtors and auditors, this turnaround looks like a movie sequel that didn’t suck.
With ROE of 66.9%, ROCE of 33.9%, and Debt to Equity of 1.83, it’s clear they’ve learned how to squeeze every rupee from their balance sheet. But before we raise a toast, remember this—promoters have pledged 71.7% of their holding. Yes, that’s the corporate equivalent of mortgaging your future for a present smile.
So what’s happening here? A Metformin empire, formulation rebirth, and a little help from Tata Capital’s ₹25 crore NCDs. Grab your popcorn, this one’s going to be wild.
2. Introduction
If you thought pharma was boring, Wanbury’s story will change your mind. It’s the tale of a once-troubled smallcap with more restructurings than Ranbir Kapoor’s hairstyles. Founded in 1988, Wanbury has navigated every storm—debt traps, losses, and ownership pledges—only to re-emerge as one of India’s stealthiest turnaround cases.
At its heart, Wanbury is a classic two-engine machine: API exports and domestic formulations. But here’s the twist—its largest API, Metformin, is not just a drug; it’s a national service. The company manufactures over 8,500 tons per year, making it one of the world’s biggest producers. Add Tramadol and Sertraline (for those dealing with stress induced by market volatility), and you’ve got a global antidepressant supplier that’s literally healing the stress created by itself.
The company’s FY25 numbers were a wake-up call to skeptics. From losses in FY23 to ₹50 crore PAT in FY25, Wanbury has rebuilt its mojo while balancing high leverage and thin margins. It’s like watching a diabetic patient run a marathon—against all odds, but full of grit.
And just when you thought they’d rest, they went ahead and issued 20 lakh warrants worth ₹24 crore to promoters, secured ₹25 crore via NCDs from Tata Capital, and launched a new iron supplement, Wanbury C RED, because why not?
3. Business Model – WTF Do They Even Do?
Wanbury operates in the global pharmaceutical space, balancing the science of molecules with the art of surviving lenders. The business splits into two verticals:
(a) API (Active Pharmaceutical Ingredient) – The crown jewel. Wanbury produces and sells APIs like Metformin, Tramadol, Sertraline, Paroxetine, and Clopidogrel to over 50 countries. Around 65% of its API revenue comes from regulated markets (US & EU). It has two US-FDA approved API plants and another for semi-regulated markets.
(b) Formulations – The desi side hustle. Wanbury markets around 70 branded drugs in India across gynecology, orthopedics, anti-diabetic, and general practitioner segments. Brands like Clavcure, Rabiplus, Coriminic, and Nurture populate doctor shelves from Delhi to Dibrugarh.
The USP? They own the chemistry and the customer—API powers exports, formulations build domestic recall. This “dual-engine” setup gives it resilience; if one market sneezes, the other doesn’t catch cold immediately.
In FY23, 87% of revenue came from finished goods (manufacturing) and 13% from traded goods. Meanwhile, exports contributed 60% and domestic sales 40%.
So yes, they’re not just selling medicines—they’re selling the hope that maybe, this year, the auditors won’t send a red flag email.
4. Financials Overview
Quarterly Results Comparison (₹ crore)
Metric
Q2 FY26 (Sep 2025)
Q2 FY25 (Sep 2024)
Q1 FY26 (Jun 2025)
YoY %
QoQ %
Revenue
160
161
163
-0.6%
-1.8%
EBITDA
26
20
24
+30.0%
+8.3%
PAT
15.2
8.0
13.0
+89.3%
+16.9%
EPS (₹)
4.35
2.45
4.10
+77.5%
+6.1%
Commentary: Profit up 89% YoY, sales flat, and EBITDA margin rising to 16%—that’s what you call a “clean pharma high.” The company seems to be handling cost control and interest burden much better than before. Interest costs dropped to ₹7 crore (down from ₹10 crore), showing refinancing at 12.5% was actually productive.
5. Valuation Discussion – Fair Value Range Only
Method 1: P/E Method Current EPS (TTM): ₹15 Industry P/E: 31.5 Wanbury’s P/E: 18.1
